Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FHDB8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal procurement competition. The contract falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion federal acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier within the federal defense medical supply chain, with its PPV-G GEN V IDC ceiling valued at $499,999,999 through December 31, 2036. The company's extensive product portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, including oncology treatments such as Xtandi, which is used in cancer therapy. As one of multiple regional prime vendors under the PPV-G GEN V framework, DMS Pharmaceutical Group serves as an authorized supplier of essential medications and medical consumables to support global Department of Defense healthcare operations. The company's established track record of performance across numerous delivery orders demonstrates its reliability in fulfilling the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHDB8?
SPE2DR26FHDB8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FHDB8 worth?
The government has obligated $17,021 on SPE2DR26FHDB8.
Is contract SPE2DR26FHDB8 an order under another contract?
Yes. SPE2DR26FHDB8 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDB8 competed?
The extent of competition for SPE2DR26FHDB8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award